南京医科大学学报（自然科学版）2026，Vol.46Issue(3)：355-365,374,12.DOI:10.7655/NYDXBNSN251274
胸腺上皮肿瘤免疫治疗进展与不良事件管理
Immunotherapy advances and adverse event management in thymic epithelial tumors
摘要
Abstract
Thymic epithelial tumor(TET)represents a rare malignant mediastinal neoplasm with limited systemic treatment options for advanced-stage patients.In recent years,immunotherapy has been widely applied in solid tumors such as lung cancer and melanoma.Clinical studies of programmed death-1/programmed death-ligand 1(PD-1/PD-L1)inhibitors in TET have also demonstrated preliminary efficacy.However,immunotherapy in TET is associated with specific and highly prevalent immune-related adverse events(irAE),severely limiting its clinical application.With advances in understanding the pathophysiology of irAE and the adoption of multidisciplinary management approaches,early recognition,tiered interventions,and personalized treatment strategies have progressively matured.The implementation of these systematic management protocols provides critical safeguards for the safe advancement of immunotherapy in TET and holds promise for further improving patient survival outcomes.This article provides a systematic review of research progress in immunotherapy for TET,the potential mechanisms underlying irAE,and comprehensive management strategies.关键词
胸腺上皮肿瘤/胸腺瘤/胸腺癌/免疫检查点抑制剂/免疫相关不良事件/生物标志物Key words
thymic epithelial tumor/thymoma/thymic carcinoma/immune checkpoint inhibitor/immune-related adverse event/biomarker分类
医药卫生引用本文复制引用
焦艺,赵廷昱,刘凌翔..胸腺上皮肿瘤免疫治疗进展与不良事件管理[J].南京医科大学学报（自然科学版）,2026,46(3):355-365,374,12.基金项目
国家自然科学基金(21575064) （21575064）
